Printer Friendly

EMPYREAN DIAGNOSTICS LTD. COMPLETES TESTS

 VANCOUVER, British Columbia, Sept. 13 /PRNewswire/ -- Company president and chief executive officer Daniel Bland, is pleased to announce that the most recent round of clinical trials, conducted by Medical Device Inspection Co. Inc. (MDI) of Great Neck, N.Y. on the Empyrean Diagnostics Inc. (EDI) proprietary HIV-1 test-kit, are complete and the results from this test on the EDI technology show 100 percent sensitivity and 99.6 percent specificity.
 This study, which consisted of more than 800 tests, was performed during a 4-week span by MDI in two separate locations, one in New York and the other in California. The evaluations were conducted following WHO (World Health Organization) protocol and were double-blind and randomized.
 A copy of the above mentioned MDI report will be made available upon request.
 Empyrean Diagnostics Inc., a wholly owned subsidiary of Empyrean Diagnostics Ltd. (Vancouver: EMD) has developed a proprietary, inexpensive, easy-to-use whole blood rapid ELISA test kit for the detection of HIV-1 and is currently licensing the manufacturing and marketing rights of the technology around the world.
 -0- 9/13/93
 /CONTACT: 800-567-8181 or 604-687-6223/
 (EMD.)


CO: Empyrean Diagnostics Ltd. ST: British Columbia IN: SU:

EH -- LA038 -- 1503 09/13/93 17:36 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 13, 1993
Words:200
Previous Article:SPORTS/LEISURE ACQUIRES EQUITY INTEREST IN FLAMINGO APPAREL
Next Article:CIPRICO ANNOUNCES HIGHER AVAILABILITY, LOWER COST DISK ARRAY
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters